United States Food and Drug Administration (USFDA) has conducted onsite inspection of pharmacovigilance and post marketing surveillance system at Zydus Lifesciences’ office based in New Jersey, USA. The inspection was conducted from September 22 to September 25, 2026. The inspection closed with NIL observations.
Zydus Lifesciences is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain of innovating, manufacturing, marketing and selling of finished dosage human formulations, active pharmaceutical ingredients (APIs), animal healthcare products and consumer wellness products.
